JP2016539089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539089A5 JP2016539089A5 JP2016521774A JP2016521774A JP2016539089A5 JP 2016539089 A5 JP2016539089 A5 JP 2016539089A5 JP 2016521774 A JP2016521774 A JP 2016521774A JP 2016521774 A JP2016521774 A JP 2016521774A JP 2016539089 A5 JP2016539089 A5 JP 2016539089A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- disease
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056102 CD100 antigen Proteins 0.000 claims description 23
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 102100034384 Plexin-B1 Human genes 0.000 claims description 6
- 101710100559 Plexin-B1 Proteins 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000028831 congenital heart disease Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 102100034383 Plexin-B2 Human genes 0.000 claims description 2
- 101710100551 Plexin-B2 Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 208000009525 Myocarditis Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889421P | 2013-10-10 | 2013-10-10 | |
| US61/889,421 | 2013-10-10 | ||
| PCT/US2014/060129 WO2015054628A1 (en) | 2013-10-10 | 2014-10-10 | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019035055A Division JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539089A JP2016539089A (ja) | 2016-12-15 |
| JP2016539089A5 true JP2016539089A5 (enExample) | 2017-11-24 |
| JP6760840B2 JP6760840B2 (ja) | 2020-09-23 |
Family
ID=52809873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521774A Active JP6760840B2 (ja) | 2013-10-10 | 2014-10-10 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
| JP2019035055A Pending JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019035055A Pending JP2019108359A (ja) | 2013-10-10 | 2019-02-28 | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9512224B2 (enExample) |
| EP (1) | EP3054976B1 (enExample) |
| JP (2) | JP6760840B2 (enExample) |
| KR (1) | KR102366682B1 (enExample) |
| CN (1) | CN105848679A (enExample) |
| AU (1) | AU2014331683B2 (enExample) |
| BR (1) | BR112016008010A2 (enExample) |
| CA (1) | CA2926944C (enExample) |
| DK (1) | DK3054976T3 (enExample) |
| EA (1) | EA037551B1 (enExample) |
| ES (1) | ES2821814T3 (enExample) |
| IL (1) | IL244976B (enExample) |
| MX (1) | MX385575B (enExample) |
| NZ (1) | NZ630881A (enExample) |
| PT (1) | PT3054976T (enExample) |
| SG (1) | SG11201602807PA (enExample) |
| WO (1) | WO2015054628A1 (enExample) |
| ZA (1) | ZA201602577B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN106474559B (zh) * | 2016-11-30 | 2019-07-12 | 西南交通大学 | 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法 |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN106983919B (zh) * | 2017-03-06 | 2019-07-12 | 西南交通大学 | 一种Sema 4D-VEGF涂层的构建方法及应用 |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| CN108499220B (zh) * | 2018-04-25 | 2020-07-31 | 山东纯江环境科技有限公司 | 石墨烯/聚丙烯非织造布过滤网制备方法及其应用 |
| CN109125731B (zh) * | 2018-10-22 | 2019-10-25 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 |
| US20230238135A1 (en) * | 2020-06-19 | 2023-07-27 | The General Hospital Corporation | Near-infrared autofluorescence imaging systems and methods |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| KR102847091B1 (ko) * | 2022-08-25 | 2025-08-21 | 부산대학교 산학협력단 | 혈관석회화 동반 만성신부전에서 세마포린 4d의 용도 |
| CN116949097B (zh) * | 2023-09-20 | 2023-12-12 | 江苏集萃药康生物科技股份有限公司 | 一种sema4d人源化小鼠模型的构建方法及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| RU2006124743A (ru) | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
-
2014
- 2014-09-11 NZ NZ630881A patent/NZ630881A/en unknown
- 2014-10-10 US US14/511,679 patent/US9512224B2/en active Active
- 2014-10-10 PT PT148530231T patent/PT3054976T/pt unknown
- 2014-10-10 BR BR112016008010A patent/BR112016008010A2/pt not_active Application Discontinuation
- 2014-10-10 CA CA2926944A patent/CA2926944C/en active Active
- 2014-10-10 ES ES14853023T patent/ES2821814T3/es active Active
- 2014-10-10 CN CN201480067853.5A patent/CN105848679A/zh active Pending
- 2014-10-10 DK DK14853023.1T patent/DK3054976T3/da active
- 2014-10-10 EP EP14853023.1A patent/EP3054976B1/en active Active
- 2014-10-10 SG SG11201602807PA patent/SG11201602807PA/en unknown
- 2014-10-10 EA EA201690728A patent/EA037551B1/ru unknown
- 2014-10-10 MX MX2016004551A patent/MX385575B/es unknown
- 2014-10-10 JP JP2016521774A patent/JP6760840B2/ja active Active
- 2014-10-10 KR KR1020167012123A patent/KR102366682B1/ko active Active
- 2014-10-10 WO PCT/US2014/060129 patent/WO2015054628A1/en not_active Ceased
- 2014-10-10 AU AU2014331683A patent/AU2014331683B2/en active Active
-
2016
- 2016-04-07 IL IL244976A patent/IL244976B/en active IP Right Grant
- 2016-04-15 ZA ZA201602577A patent/ZA201602577B/en unknown
-
2019
- 2019-02-28 JP JP2019035055A patent/JP2019108359A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539089A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2015212281A5 (enExample) | ||
| JP2019059786A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2009518005A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2011518125A5 (enExample) | ||
| JP2018504907A5 (enExample) | ||
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2013198490A5 (enExample) | ||
| JP2016183160A5 (enExample) | ||
| JP2019504032A5 (enExample) | ||
| JP2010535205A5 (enExample) | ||
| JP2016063812A5 (enExample) | ||
| JP2015504421A5 (enExample) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2015514110A5 (enExample) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| JP2016512214A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| JP2015524816A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| JP2014530215A5 (enExample) |